Lundbeck to Detail Movement Disorder Pipeline at MDS 2026

The company’s presentation lineup focuses on the MASCOT trial, a global Phase III study investigating amlenetug for the treatment of multiple system atrophy (MSA). Researchers will share baseline characteristics from the 401-participant cohort, providing a comprehensive look at the trial’s reach across MSA-C and MSA-P variants. Beyond clinical trial data, Lundbeck aims to address the diagnostic and economic hurdles associated with the rare neurodegenerative condition, including new research on cerebrospinal fluid biomarkers and evidence of the high healthcare resource utilization burden inherent to the disease.

In the realm of Parkinson's disease, the company will report Phase Ib results for Lu AF28996, an oral D1-like/D2-like dopamine receptor agonist currently under investigation to manage motor fluctuations and dyskinesia. The findings include 18-week open-label data and preclinical primate studies, offering a clearer picture of the compound's potential to bridge existing treatment gaps in patients who no longer respond optimally to standard levodopa therapy.